Effects of fosaprepitant (Fosa) administered as single dose versus two doses, on nausea/vomiting (N/V) in patients receiving multiday chemotherapy (CT) with a highly emetogenic regimen of doxorubicin and ifosafamide (AI): Randomized cross-over study.
Saroj Vadhan-Raj
Research Funding - Merck
Xiao Zhou
No relevant relationships to disclose
Dejka M. Araujo
No relevant relationships to disclose
Neeta Somaiah
No relevant relationships to disclose
Anthony Paul Conley
No relevant relationships to disclose
Vinod Ravi
No relevant relationships to disclose
Mary Daniel
No relevant relationships to disclose
Robert S. Benjamin
Stock Ownership - Merck (I)
Shreyaskumar Patel
Consultant or Advisory Role - GlaxoSmithKline; Johnson & Johnson; Novartis
Research Funding - Astex Therapeutics; Eisai; Infinity Pharmaceuticals; Johnson & Johnson; Morphotek; PharmaMar